Eric P. Winer

A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine resistant metastatic breast cancer

Abstract Background Patients with endocrine-resistant hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) have limited effective treatment options. Heat shock protein 90 (HSP90) regulates estrogen receptor stability and function; its inhibition has been...